이수앱지스

086890KOSDAQ의료용품 및 기타 의약 관련제품 제조업

52.8 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but Revenue metrics are weak. Plunged 29.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Isu Appgis primarily operates in the pharmaceutical sector, focusing on key products such as Absorcin (for Gaucher disease), Fabrazyme (for Fabry disease), and Clotyplast (an antibody therapy for cardiovascular conditions). In 2024, sales reached 60.3 billion won, a 11% increase from the previous year, with product sales accounting for 86.3% of total revenue. Product prices have remained stable over the past three years.

Number of Employees

190people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

1.13Industry Average 1.304.0Point

In line with industry avg

ROE

-9.92Industry Average -4.893.5Point

2.0x industry avg (excellent)

Debt Ratio

6.96Industry Average 6.862.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲78.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.9% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
이수앱지스, 파브리병 인식 개선 캠페인 ‘댓글하나·기부하나’ 전문...
이수앱지스의 파브리병 인식 개선 캠페인 성공으로 기업 이미지 향상 및 사회적 가치 창출 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,160Won52-week high 6,24052-week low 3,160

1-month return0.0Point

1m -29.86% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15